Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06664178 in Advanced Solid Tumors
NCT02122146Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Aug 2014
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06664178 in solid tumor, non-small cell lung cancer (NSCLC), ovarian cancer and 1 more, sponsored by Pfizer. Primary endpoint: First Cycle Dose Limiting Toxicities. Started Aug 2014; status: terminated.
02
Drugs
PF-06664178
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT02122146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122146.